Prevention of thromboembolic complications in hormonal contraception in women over 35 years
Objective. To assess the effects of combined oral contraceptives that contain micronized ethinylestradiol (20 mg) and drospirenone (3 mg) in combination with dipyridamole (75 mg) for indicators of hemostasis in women older than 35 years. Subjects and methods. Research of the hemostasis system with the use of combined oral contraceptives (90 healthy women 36-45years): Group I(45 patients) - have received COC in combination with dipyridamole; Group II(45 patients) - only COC. Used: APTT, prothrombin test, Thrombin time, Fibrinogen concentration, activity of factor VIII, activity of antithrombin, resistance to activated protein c. Results. In the second group was not increase prothrombin ratio determination test and level of Antithrombin found in patients in Group I, group II also increased the activity of factor VIII from the original target and activity antithrombin declined (in Group I it had downward trend). In addition, in the II group index Ars-resistance through 6 and 12 months was below both the source data and the limits of normal values. Conclusion. Application of combined oral contraceptives does not cause clinically significant changes of the hemostatic system, but the combination of the COC, together with dipyridamole helps reduce thrombophilia impact of hormonal contraceptives.